Business
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor
About this update from Pharvaris N.v.
[{"type":"text","content":"ZUG, Switzerland, July 21, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today shared data from the RAPIDe-1 Phase 2 clinical study of PHVS416 (deucrictibant immediate-release capsules) for the on-demand treatment of HAE attacks, including data focused on time-to-symptom relief and resolution of HAE attacks, in two poster presentations at the 2023 U.S. HAEA National Summit, taking place in Orlando, Florida from July 20-23. Presentation details: Title: Efficacy and safety of bradykinin B2 receptor antagonism with deucrictibant immediate-release capsule for treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trialPresenter: Marc A. Riedl, M.D., M.S.Poster ID: #6 Title: Treatment with oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule improves hereditary angioedema attack symptomsPresenter: John Anderson, M.D.Poster ID: #26 The presentations will take place in the hallway outside of the Professional-Scientific Track room, Gatlin A2/A3, at Rosen Shingle Creek in Orlando, on Friday, July 21, from 9:50-10:20 a.m. EDT. The posters will be available for viewing from Friday, July 21, at 7:45 a.m. EDT to Saturday, July 22, at 12:30 p.m. EDT, and will be made publicly available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. About PharvarisBuilding on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE safe, effective, and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/. Forward-Looking StatementsThis press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking...